-26%

est. 2Y upside i

Healthcare

'Figma/Canva for scientists’

Rank

#2439

Sector

Life Sciences Design Software

Est. Liquidity

~2Y

Data Quality

Data: High

BioRender presents a moderate upside opportunity for a job seeker.

Last updated: March 10, 2026

Bull (30%)+100%

BioRender successfully leverages its AI integrations and Anthropic partnership to expand its 'visual language of science' into new research domains and enterprise solutions, driving revenue to over $100M by 2028 and achieving a $2.0B valuation through an IPO or strategic acquisition, reflecting its market leadership and strong moat.

Base (45%)+40%

BioRender maintains its strong position in the life sciences design software market, growing revenue steadily to approximately $60M by 2028. The company continues to be profitable, but a slight normalization of its high valuation multiple results in a $1.4B valuation, offering moderate returns for common stock holders.

Bear (25%)-40%

Increased competition from AI-powered tools like Illustrae and expanded scientific offerings from incumbents like Adobe or Canva lead to pricing pressure and slower growth. Revenue stalls below $50M, and the high valuation multiple contracts significantly, resulting in a down round or acquisition at a $600M valuation, severely impacting common stock value given the substantial liquidation preferences.

Est. time to liquidity~2.0 years

Preference Stack Risk

severe

Funding Intensity

2%

Investors hold $1.0B in liquidation preferences ahead of common stock, representing 100% of the current valuation.

Dilution Risk

high

Given the substantial $1.0B funding round, there's a high risk of significant dilution for existing common stock holders if future rounds are needed at a lower valuation or if the company's growth doesn't significantly outpace this funding.

Secondary Liquidity

active

BioRender offered over 100 employees the opportunity to realize liquidity from their vested equity as part of the December 2025 investment, indicating an active secondary market.

View all 2 open roles at BioRender →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on BioRender's data — designed to show you've done your homework.

  • 1

    “How does BioRender plan to maintain its strong competitive moat and differentiate itself against emerging AI-powered scientific illustration tools like Illustrae, and potential expansion by general design platforms like Adobe or Canva?”

  • 2

    “Given the significant recent funding and the current valuation multiple of ~25.7x revenue, what are the key growth levers the company is focusing on to justify and exceed this valuation in the next 2-3 years, particularly in terms of expanding beyond its core academic and biopharma users?”

  • 3

    “With the recent opportunity for employees to realize liquidity as part of the Dimension Capital investment, how does the company envision future liquidity events for employees, and what is the anticipated timeline for such events (e.g., IPO or acquisition)?”

Community

Valuation Sentiment

Our model estimates -26% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.